These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2908757)

  • 1. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome.
    Prior A; Wilson KM; Whorwell PJ
    Aliment Pharmacol Ther; 1988 Dec; 2(6):535-9. PubMed ID: 2908757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised double-blind placebo-controlled trial of lidamidine HCL in irritable bowel syndrome.
    Awad RA; Llorens F; Camelo AL; Sánchez M
    Acta Gastroenterol Latinoam; 2000; 30(3):169-75. PubMed ID: 10975022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of irritable colon with lidamidine and support psychotherapy].
    Rodríguez Magallán A; Valadéz Velázquez T; Llorens Torres F; Sánchez Torres MI
    Rev Gastroenterol Mex; 1997; 62(1):7-13. PubMed ID: 9190662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study.
    Baldi F; Longanesi A; Blasi A; Monello S; Cestari R; Missale G; Corazziari E; Badiali G; Marzio L; Di Felice F
    Hepatogastroenterology; 1992 Oct; 39(5):392-5. PubMed ID: 1459516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double blind study of ispaghula in irritable bowel syndrome.
    Prior A; Whorwell PJ
    Gut; 1987 Nov; 28(11):1510-3. PubMed ID: 3322956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the safety and effectiveness of WHR-1142A in the treatment of non-specific acute diarrhea].
    Heredia Díaz JG; Alcántara I; Solís A
    Rev Gastroenterol Mex; 1979; 44(4):167-73. PubMed ID: 394268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride).
    Page JG; Dirnberger GM
    J Clin Gastroenterol; 1981 Jun; 3(2):153-6. PubMed ID: 7016973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Domperidone treatment in the irritable bowel syndrome.
    Fielding JF
    Digestion; 1982; 23(2):125-7. PubMed ID: 6284574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium polycarbophil compared with placebo in irritable bowel syndrome.
    Toskes PP; Connery KL; Ritchey TW
    Aliment Pharmacol Ther; 1993 Feb; 7(1):87-92. PubMed ID: 8439642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome.
    Ferrari A; Cavallero M; Spandre M; Gemme C; Rossini FP; Imbimbo BP
    Clin Ther; 1986; 8(3):320-8. PubMed ID: 3521859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral domperidone: double blind comparison with placebo in irritable bowel syndrome.
    Cann PA; Read NW; Holdsworth CD
    Gut; 1983 Dec; 24(12):1135-40. PubMed ID: 6357963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome.
    Dunlop SP; Jenkins D; Neal KR; Naesdal J; Borgaonker M; Collins SM; Spiller RC
    Aliment Pharmacol Ther; 2003 Jul; 18(1):77-84. PubMed ID: 12848628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zamifenacin (UK-76, 654) a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome.
    Houghton LA; Rogers J; Whorwell PJ; Campbell FC; Williams NS; Goka J
    Aliment Pharmacol Ther; 1997 Jun; 11(3):561-8. PubMed ID: 9218083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind crossover comparison of lidamidine, loperamide and placebo for the control of chronic diarrhoea.
    Allison MC; Sercombe J; Pounder RE
    Aliment Pharmacol Ther; 1988 Aug; 2(4):347-51. PubMed ID: 2979258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lidamidine hydrochloride and loperamide on gastric emptying and transit of the small intestine. A double-blind study.
    Sninsky CA; Davis RH; Clench MH; Thomas KD; Mathias JR
    Gastroenterology; 1986 Jan; 90(1):68-73. PubMed ID: 3940258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction.
    Jalihal A; Kurian G
    J Gastroenterol Hepatol; 1990; 5(5):507-13. PubMed ID: 2129822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study.
    Steadman CJ; Talley NJ; Phillips SF; Zinsmeister AR
    Mayo Clin Proc; 1992 Aug; 67(8):732-8. PubMed ID: 1434911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial.
    Awad R; Dibildox M; Ortiz F
    Acta Gastroenterol Latinoam; 1995; 25(3):137-44. PubMed ID: 8600700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double blind trial of trimebutine in the irritable bowel syndrome.
    Fielding JF
    Ir Med J; 1980 Oct; 73(10):377-9. PubMed ID: 7000730
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome.
    Awad RA; Cordova VH; Dibildox M; Santiago R; Camacho S
    Acta Gastroenterol Latinoam; 1997; 27(4):247-51. PubMed ID: 9401097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.